Patrick A. Baeuerle

Patrick A. Baeuerle is the inventor of BiTE (bispecific T-cell engager) technology and one of the most influential figures in cancer immunotherapy. As founding CSO of Micromet, he led development of blinatumomab from concept to FDA approval in 2014. The Micromet acquisition by Amgen in 2012 for $1.16 billion validated BiTE technology commercially. He has published over 300 papers with 88,000+ citations (h-index 145), ranking in the top 0.01% of most-cited scientists globally. Baeuerle is a member of the German National Academy of Sciences Leopoldina and EMBO, and continues shaping the field as co-founder of Cullinan Oncology focusing on next-generation immunotherapy.

Patrick A. Baeuerle博士是BiTE（双特异性T细胞衔接器）技术的发明者，也是癌症免疫治疗领域最具影响力的人物之一。作为Micromet的创始首席科学官，他领导了blinatumomab从概念到2014年FDA批准的开发。2012年安进以11.6亿美元收购Micromet，验证了BiTE技术的商业价值。他发表了300多篇论文，被引用88,000次以上（h指数145），位列全球被引用次数最多的科学家前0.01%。Baeuerle是德国国家科学院Leopoldina和EMBO成员，目前作为Cullinan Oncology联合创始人继续塑造该领域。